{"id":981708,"date":"2026-07-15T09:20:16","date_gmt":"2026-07-15T13:20:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-receives-new-u-s-patent-allowance-expected-to-provide-protection-into-july-2044-for-zusduri-and-ugn-103\/"},"modified":"2026-07-15T09:20:16","modified_gmt":"2026-07-15T13:20:16","slug":"urogen-receives-new-u-s-patent-allowance-expected-to-provide-protection-into-july-2044-for-zusduri-and-ugn-103","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-receives-new-u-s-patent-allowance-expected-to-provide-protection-into-july-2044-for-zusduri-and-ugn-103\/","title":{"rendered":"UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI\u2122 and UGN-103"},"content":{"rendered":"
\n

PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application no. 18\/784,354 entitled \u201cTreatment of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer With a Thermally Gelling Pharmaceutical Composition Containing Mitomycin.\u201d The allowed claims cover methods of treating patients with recurrent, low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) without a transurethral resection of a bladder tumor (TURBT), supported by data from the ENVISION and ATLAS clinical trials. The U.S. patent, once issued, will have an expiration date in July 2044.<\/p>\n

\u201cThis patent allowance further strengthens the intellectual property foundation supporting ZUSDURI and our UGN-103 investigational medicine, if approved, and underscores the innovation behind our proprietary RTGel<\/em>\u00ae<\/em><\/sup> technology,\u201d said Liz Barrett, President and Chief Executive Officer of UroGen. \u201cSupported by data from the ENVISION and ATLAS trials of ZUSDURI, these patent claims reflect the ability of our RTGel<\/em>-based technology to deliver mitomycin as a primary, non-surgical treatment option for adults with recurrent LG-IR-NMIBC without a TURBT. We believe this approach helps patients achieve highly durable recurrence-free intervals while reducing the burden of repeat surgical interventions.\u201d<\/p>\n

Building on the growing body of clinical evidence supporting ZUSDURI and UGN-103, UroGen remains focused on advancing its proprietary RTGel<\/em> technology and developing innovative therapies that have the potential to expand non-surgical treatment options for patients with urothelial cancers and strengthen the company\u2019s long-term growth opportunities.<\/p>\n

\n About ZUSDURI
<\/strong>ZUSDURI (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, approved for the treatment of adults with recurrent LG-IR-NMIBC. Utilizing UroGen\u2019s proprietary\u00a0RTGel<\/em>\u00a0technology (a sustained release, hydrogel-based formulation), ZUSDURI is delivered directly into the bladder by a trained healthcare professional using a urinary catheter in an outpatient setting, thereby enabling the treatment of tumors by non-surgical means.<\/p>\n

\n About UGN-103<\/strong>
\n
In\u00a0January 2024, UroGen entered into a licensing and supply agreement with medac to develop UGN-103 for recurrent LG-IR-NMIBC. UGN-103 is designed to reinforce and extend the clinical and commercial profile of ZUSDURI, the first and only FDA-approved treatment for adults with recurrent LG-IR-NMIBC. The program maintains UroGen\u2019s innovative and proven\u00a0RTGel<\/em>\u00a0technology, enabling sustained mitomycin exposure in the bladder, while incorporating next-generation enhancements, including a more streamlined manufacturing process and simplified reconstitution to support improved ease of use in clinical practice. UroGen holds\u00a0U.S.\u00a0patents covering the combination of its proprietary\u00a0RTGel<\/em>\u00a0technology with medac\u2019s licensed lyophilized mitomycin formulation, as well as the use of UGN-103 in LG-IR-NMIBC, with intellectual property protection expected to extend into\u00a0December 2041.<\/p>\n

\n About<\/strong>\u00a0UroGen<\/strong>\u00a0Pharma<\/strong>\u00a0Ltd.<\/strong>
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed\u00a0RTGel\u00a0<\/em>reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen\u2019s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and our second product, ZUSDURI (mitomycin) for intravesical solution for adult patients with recurrent LG-IR-NMIBC, are designed to ablate tumors by non-surgical means. UroGen is headquartered in\u00a0Princeton, NJ\u00a0with operations in\u00a0Israel.<\/p>\n

Visit\u00a0www.UroGen.com<\/a>\u00a0to learn more or follow us on X (formerly Twitter), @UroGenPharma.<\/p>\n

\n About\u00a0medac <\/strong>
\n
At medac group, we believe that health is humanity\u2019s most valuable resource. Since 1970, our mission has been to improve patients\u2019 quality of life worldwide by making the best medical treatments available. As a globally operating pharmaceutical company headquartered in Germany, we provide high-quality medical treatments for patients worldwide in over 90 countries. With more than 2,000 employees, we are committed to improving human health.<\/p>\n

Our products are manufactured in Germany and other European countries to the highest standards, utilizing our own logistics center and production sites, and subsequently distributed worldwide.<\/p>\n

We are constantly working to improve authorized medicines and to develop innovative therapies in the fields of rheumatology, urology, hematology, and oncology. Part of our mission is to provide safe, high-quality and innovative original products, as well as generics and biosimilars. In this way, we make vital treatments accessible to those affected.<\/p>\n

For more information, please visit\u00a0www.medac-group.com.<\/strong><\/a><\/p>\n

\n APPROVED USE FOR ZUSDURI<\/strong>
\n
ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after previously receiving bladder surgery to remove tumor that did not work or is no longer working.<\/p>\n

\n IMPORTANT SAFETY INFORMATION<\/strong>\n <\/p>\n

\n You should not receive ZUSDURI if you<\/strong>\u00a0have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI.<\/p>\n

\n Before receiving ZUSDURI, tell your healthcare provider about all of your medical conditions, including if you:<\/strong>\n <\/p>\n